The RESET RA study highlights the potential of vagus nerve stimulation as a novel treatment for rheumatoid arthritis, showing significant improvements in ACR20 response rates and DAS28-CRP LDA/remission rates. With FDA approval anticipated as early as 2025, this treatment could offer a new option for patients, especially those refractory to current therapies.